Olokizumab Tops Placebo for RA Patients Receiving Methotrexate

THURSDAY, Aug. 25, 2022 -- Olokizumab is superior to placebo and noninferior to adalimumab in patients with rheumatoid arthritis receiving maintenance methotrexate, according to a study published in the Aug. 25 issue of the New England Journal of...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news